PRISM Receives Milestone: Generates Small Molecule...

Successful generation of INVA8003, a peptidomimetic inhibitor of PYCARD

July 20, 2021

Sosei Heptares and InveniAI Enter a Multi-Target AI-Powered...

Tokyo, Japan, and Cambridge, UK, 6 July 2021 – Sosei Group Corporation (“the Company”; TSE: 4565),

July 06, 2021

InveniAI Appoints Industry Leader...

GUILFORD, Conn., May 11, 2021 (GLOBE NEWSWIRE) -- InveniAI® LLC, a global

May 11, 2021

InveniAI and Shionogi Enter AI-Powered...

Teams will work together by leveraging InveniAI's technology

April 27, 2021

InveniAI and Kyowa Kirin Enter...

Expansion of existing collaboration will leverage InveniAI

December 09, 2020

InveniAI and PRISM Biolab Initiate A…

Guilford, Conn., September 9, 2020, InveniAI® LLC (InveniAI), a global leader in pioneering the application of artificial

September 09, 2020

InveniAI Enters Strategic Artificial...

Three-year strategic collaboration to leverage InveniAI’s AI

July 29, 2020

InveniAI Announces Strategic Partnership...

TB Alliance to leverage AlphaMeld®, an AI-powered platform

June 02, 2020

InveniAI introduces New Products To...

TargetMeld™ and RxMeld™ to provide predictive analytics and comprehensive access to emerging targets

November 06, 2019

InveniAI Launches Suite of Products...

InveniAI Launches Suite of Products Powered by AlphaMeld®

September 17, 2019

InveniAI Appoints Industry Veteran...

Dr. Agrawal, a biopharma Strategy and R&D leader, brings scientific and technology

July 02, 2019

InveniAI to be featured at the...

Focus on identifying therapies in hard to treat diseases to serve unmet patient needs

May 29, 2019

Microsoft Features InveniAI in their...

GUILFORD, CT., March 26, 2019 — InveniAI® Corporation, a global leader pioneering the application

March 06, 2019

InveniAI Featured in The Guardian’s…

GUILFORD, Conn., Mar. 01, 2019 — InveniAI® Corporation, a global leader in pioneering the application of artificial

March 01, 2019

InveniAI Enters Strategic Artificial…

Guilford, Conn., September 9, 2020, InveniAI® LLC (InveniAI), a global leader in pioneering the application of artificial

December 11, 2018

Beyond Celiac Town Hall—Uncovering Diversity and Disparity in Celiac Disease, with NMQF

InveniAI’s CSO discussing diversity and disparity and increasing diagnosis rates for celiac disease in the US in a town hall meeting at

July 11, 2021

BioCT Stories Behind the Science: A Conversation with Aman Kant

InveniAI’s CBO, Aman Kant, featured in BioCT’s The Stories Behind the Science series where he shares his academic and professional journey to date.

July 10, 2021

Sosei Heptares and InveniAI Enter a Multi-target AI-powered...

Creating transformative therapeutics for immune diseases by combining InveniAI's validated AI-based platform,

July 06, 2021

Sosei Heptares Turns To AI In GPCR-Focused...

Sosei Heptares hopes to create transformative therapeutics for immune diseases by combining its GPCR structure

July 06, 2021

Sosei taps into new wave of AI-driven...

A new R&D collaboration between Japanese drugmaker Sosei Group and USA-based InveniAI will see the firms

July 06, 2021

InveniAI…

Krishnan Nandabalan, Ph.D., President and CEO, InveniAI, LLC., Keynote Speaker at TEDxUNewHaven, “Looking at Tomorrow from Today,” April 17, 2021

April 17, 2021

InveniAI picks new chief scientific…

Guilford-based company InveniAI LLC, which uses artificial intelligence for drug discovery and

May 14, 2021

InveniAI and Kyowa Kirin partner…

InveniAI and Kyowa Kirin recently reported an expansion of a collaboration agreement, using InveniAI’s

January 27, 2021

AI In The Time Of Covid-19: Honing In…

Dr. Krishnan Nandabalan talks to Tilde Cafe attendees about the benefits of using AI to identify

May 26, 2020

Innovations in COVID-19 Diagnostics…

After a bumpy start to testing for COVID-19, the global healthcare community has banded together

April 13, 2020

Could TLR7 Agonism be an Effective…

Introduction: An outbreak of respiratory illness (COVID-19 Disease) caused by a novel coronavirus,

March 26, 2020

AI-Powered Analytics Can Leapfrog…

As countries scramble to address the coronavirus outbreak that started in Wuhan, China, the U.S. FDA issued

March 04, 2020

From Buzzword to Clinical Tool: Setting…

Artificial intelligence (AI) far too often pops up as a term used vaguely to refer to any process that appears

January 29, 2020

QCR's Titan Thought Leader Podcast…

AI’s Role In Redefining Consumer Health & Drug evelopment-Featured Guest Krishnan Nandabalan

November 05, 2019

InveniAI Corporation helping to…

InveniAI Corporation CEO Krishnan Nandabalan sat down with Proactive at the 2019 BIO Investor Forum in San Francisco.

October 28, 2019

Krishnan Nandabalan interviewed by…

Among the many examples of Artificial Intelligence, AI in healthcare is clearly one of the leaders.

October 09, 2019

Krishnan Nandabalan interview with…

Thank you Moira Gunn for a wonderful conversation with our President and CEO,

September 29, 2019

DisruptorDaily Features InveniAI in AI Healthcare…

This interview is part of our new AI in Healthcare series, where we interview the world’s top

August 30, 2019

How AI is Transforming Clinical Trials…

Some biopharmaceutical enterprises are taking a leap of faith by reviving failed

August 12, 2019

Daniel Levine, principal of the…

Daniel Levine, principal of the Levine Media Group, and host of Bio Report and RARECast podcasts

June 04, 2019

Russo Partners featured interview…

Wading through oceans of information can be difficult if not impossible for

May 30, 2019

Could artificial intelligence…

To date, the healthcare industry has had limited success in developing treatments for rare diseases.

May 30, 2019

Invited to attend Exclusive Bloomberg…

Invited to attend Exclusive Bloomberg Digital Disruption Think Tank Meet

May 21, 2019

Startups Using Artificial Intelligence…

Artificial intelligence and machine learning platform to drive innovation for rare disease

February 29, 2019

Kyowa Hakko Kirin signs AI drug R&D deal…

BRANFORD, CT December 11, 2018, InveniAI® Corporation, a global leader in pioneering the

January 11, 2019

Here are some conferences and events our team will be attending!

BIO Digital

Jun 10-11 & 14-18, 2021

For media investor inquires

Anita Ganjoo

Director, Corporate Communications

aganjoo@inveniai.com

InvenAI Microsoft...

September 17, 2019

AlphaMeld...

September 17, 2019